Hutchison China MediTech (Chi-Med) has initiated the first-in-human Phase I clinical trial in Australia of HMPL-453, a novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR). The first drug dose was administered on February 14, 2017.
